title: Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside.
abstract: Some humans develop the axonal form of Guillain-Barré syndrome after receiving bovine brain ganglioside. On sensitization with the ganglioside mixture, all of a group of rabbits injected developed high anti-GM1 IgG antibody titers, flaccid limb weakness of acute onset, and a monophasic illness course. Pathological findings for the peripheral nerves showed predominant Wallerian-like degeneration, with neither lymphocytic infiltration nor demyelination. IgG was deposited on the axons of the anterior roots, and GM1 was proved to be present on the axons of peripheral nerves. Sensitization with purified GM1 also induced axonal neuropathy, indicating that GM1 was the immunogen in the mixture. A model of human axonal Guillain-Barré syndrome has been established that uses inoculation with a bovine brain ganglioside mixture or isolated GM1. This model may help to clarify the molecular pathogenesis of the syndrome and to develop new treatments for it.
authors.affiliation: Department of Neurology, Dokkyo University School of Medicine, Tochigi, Shimotsuga, Japan. yuki@dokkyomed.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Yuki
authors.forename: M
authors.initials: M
authors.lastname: Yamada
authors.forename: M
authors.initials: M
authors.lastname: Koga
authors.forename: M
authors.initials: M
authors.lastname: Odaka
authors.forename: K
authors.initials: K
authors.lastname: Susuki
authors.forename: Y
authors.initials: Y
authors.lastname: Tagawa
authors.forename: S
authors.initials: S
authors.lastname: Ueda
authors.forename: T
authors.initials: T
authors.lastname: Kasama
authors.forename: A
authors.initials: A
authors.lastname: Ohnishi
authors.forename: S
authors.initials: S
authors.lastname: Hayashi
authors.forename: H
authors.initials: H
authors.lastname: Takahashi
authors.forename: M
authors.initials: M
authors.lastname: Kamijo
authors.forename: K
authors.initials: K
authors.lastname: Hirata
mesh_terms: D000818:Animals; D000906:Antibodies / Q000097:blood / Q000276:immunology; D000918:Antibody Specificity; D001323:Autoantibodies / Q000096:biosynthesis / Q000276:immunology; D001369:Axons / Q000276:immunology / Q000473:pathology*; D002417:Cattle; D002634:Chemotaxis, Leukocyte; D004195:Disease Models, Animal; D005677:G(M1) Ganglioside / Q000276:immunology*; D020275:Guillain-Barre Syndrome / Q000276:immunology* / Q000473:pathology* / Q000503:physiopathology; D007114:Immunization; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007075:Immunoglobulin M / Q000097:blood / Q000276:immunology; D007150:Immunohistochemistry; D008297:Male; D018908:Muscle Weakness / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D010525:Peripheral Nerves / Q000276:immunology / Q000473:pathology; D011817:Rabbits; D014855:Wallerian Degeneration / Q000276:immunology / Q000473:pathology / Q000503:physiopathology
chemical_list: D000906:Antibodies; D001323:Autoantibodies; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D005677:G(M1) Ganglioside